000304994 001__ 304994
000304994 005__ 20251104152114.0
000304994 0247_ $$2doi$$a10.2967/jnumed.125.270267
000304994 0247_ $$2pmid$$apmid:40998729
000304994 0247_ $$2ISSN$$a0097-9058
000304994 0247_ $$2ISSN$$a0022-3123
000304994 0247_ $$2ISSN$$a0161-5505
000304994 0247_ $$2ISSN$$a1535-5667
000304994 0247_ $$2ISSN$$a2159-662X
000304994 0247_ $$2altmetric$$aaltmetric:181720231
000304994 037__ $$aDKFZ-2025-01985
000304994 041__ $$aEnglish
000304994 082__ $$a610
000304994 1001_ $$aViering, Oliver$$b0
000304994 245__ $$aBiodistribution and Radiation Dosimetry of [68Ga]Ga-RAYZ-8009, a Glypican 3-Targeting Compound for Imaging of Hepatocellular Carcinoma.
000304994 260__ $$aNew York, NY$$bSoc.$$c2025
000304994 3367_ $$2DRIVER$$aarticle
000304994 3367_ $$2DataCite$$aOutput Types/Journal article
000304994 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1762266023_1126685
000304994 3367_ $$2BibTeX$$aARTICLE
000304994 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000304994 3367_ $$00$$2EndNote$$aJournal Article
000304994 500__ $$a2025 Nov 3;66(11):1737-1742
000304994 520__ $$aGlypican 3 is highly expressed in hepatocellular carcinoma (HCC), rendering it a promising target for disease imaging. [68Ga]Ga-RAYZ-8009 is a recently introduced PET tracer selective for glypican 3. To further assess the safety and suitability of this radiopharmaceutical in a clinical setting, whole-body distribution and radiation dosimetry were evaluated. Methods: Six patients with histologically confirmed HCC or clinical or imaging-based suspicion of HCC were intravenously injected with 103-167 MBq of [68Ga]Ga-RAYZ-8009 (mean ± SD, 150 ± 22 MBq). Whole-body PET/CT scans were acquired at 10 min, 1 h, 2 h, 4 h, and 7 h after tracer injection. Time-activity curves per organ were determined, and mean organ-absorbed doses and effective doses were calculated using IDAC-Dose 2.1. Results: Injection of a standard activity of 150 MBq of [68Ga]Ga-RAYZ-8009 resulted in a median effective dose of 3.6 mSv for the male reference phantom. The highest absorbed organ doses were observed in the kidneys (median of 0.175 mGy/MBq and 0.179 mGy/MBq for male and female reference phantom, respectively), followed by the red bone marrow (median of 0.044 mGy/MBq for male/female reference phantom) and the stomach wall (median of 0.060 and 0.062 mGy/MBq for male and female reference phantom, respectively). Conclusion: [68Ga]Ga-RAYZ-8009 demonstrates a favorable biodistribution and dosimetry in patients with HCC.
000304994 536__ $$0G:(DE-HGF)POF4-899$$a899 - ohne Topic (POF4-899)$$cPOF4-899$$fPOF IV$$x0
000304994 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000304994 650_7 $$2Other$$aHCC
000304994 650_7 $$2Other$$a[68Ga]Ga-RAYZ-8009
000304994 650_7 $$2Other$$aglypican 3
000304994 650_7 $$2Other$$ahepatocellular carcinoma
000304994 650_7 $$2Other$$aradiation dosimetry
000304994 7001_ $$aBrosch-Lenz, Julia$$b1
000304994 7001_ $$0P:(DE-HGF)0$$aBundschuh, Ralph A$$b2
000304994 7001_ $$aScholtissek, Helen$$b3
000304994 7001_ $$aEnke, Johanna S$$b4
000304994 7001_ $$aAmerein, Adriana$$b5
000304994 7001_ $$aWienand, Georgine$$b6
000304994 7001_ $$aDierks, Alexander$$b7
000304994 7001_ $$aKircher, Malte$$b8
000304994 7001_ $$aPatt, Marianne$$b9
000304994 7001_ $$aPfob, Christian H$$b10
000304994 7001_ $$aLapa, Constantin$$b11
000304994 773__ $$0PERI:(DE-600)2040222-3$$a10.2967/jnumed.125.270267$$gp. jnumed.125.270267 -$$n11$$p1737-1742$$tJournal of nuclear medicine$$v66$$x0097-9058$$y2025
000304994 909CO $$ooai:inrepo02.dkfz.de:304994$$pVDB
000304994 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000304994 9131_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000304994 9141_ $$y2025
000304994 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ NUCL MED : 2022$$d2025-01-01
000304994 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-01
000304994 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-01
000304994 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-01
000304994 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2025-01-01
000304994 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-01
000304994 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2025-01-01
000304994 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2025-01-01
000304994 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-01-01
000304994 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-01
000304994 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-01
000304994 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bJ NUCL MED : 2022$$d2025-01-01
000304994 9201_ $$0I:(DE-He78)DD01-20160331$$kDD01$$lDKTK Koordinierungsstelle Dresden$$x0
000304994 980__ $$ajournal
000304994 980__ $$aVDB
000304994 980__ $$aI:(DE-He78)DD01-20160331
000304994 980__ $$aUNRESTRICTED